{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:14:15Z","timestamp":1780582455335,"version":"3.54.1"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T00:00:00Z","timestamp":1466467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs. The vinca alkaloid vincristine is a standard component of chemotherapy regimens used to treat ALL, because of its well-defined mechanism of action, demonstrated anticancer activity, and ability to be combined with other agents. However, the dosage of vincristine is frequently capped because of neurotoxicity concerns, and patients with large body surface areas are, therefore, almost always underdosed. Liposomal formulations have the ability to \u201cpassively\u201d accumulate at sites of increased vasculature permeability and reduce the adverse effects of encapsulated relative to free drug. Vincristine sulfate liposome injection (VSLI) is a sphingomyelin\/cholesterol-based liposome-encapsulated formulation that is delivered weekly in a 1-hour infusion. Based on the pharmacokinetics of the liposomal delivery system, vincristine is slowly released from the liposome and delivered into the tissues more efficiently than with the standard preparation, allowing a higher dose. This increase in therapeutic index from reduced toxicity is a valuable difference between the two formulations. VSLI is indicated for the treatment of adults with second or greater relapse and clinically advanced Philadelphia chromosome-negative ALL. For the first time, studies will be able to exploit the delivery of higher and uncapped doses of vincristine in randomized studies comparing first-line chemotherapy with standard vincristine versus VSLI in both ALL and lymphoma to determine whether VSLI is superior to conventional vincristine.<\/jats:p>","DOI":"10.1634\/theoncologist.2015-0391","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T21:24:12Z","timestamp":1466630652000},"page":"840-847","source":"Crossref","is-referenced-by-count":73,"title":["Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia"],"prefix":"10.1093","volume":"21","author":[{"given":"Dan","family":"Douer","sequence":"first","affiliation":[{"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,6,21]]},"reference":[{"key":"2021122309524252100_B1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/asheducation.V2012.1.382.3798359","article-title":"When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?","volume":"2012","author":"Lazarus","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122309524252100_B2","first-page":"1409","volume-title":"Williams Hematology","author":"Pui","year":"2010","edition":"8th ed."},{"key":"2021122309524252100_B3","first-page":"4361","article-title":"Vincristine sulfate liposomal injection for acute lymphoblastic leukemia","volume":"8","author":"Raj","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"2021122309524252100_B4","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"2021122309524252100_B5","first-page":"6","article-title":"Study on cytogenetic changes with relation to FAB classification in 397 patients with acute leukemias [in Chinese]","volume":"19","author":"Huo","year":"2011","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2021122309524252100_B6","doi-asserted-by":"crossref","first-page":"e2014073","DOI":"10.4084\/mjhid.2014.073","article-title":"Diagnosis and subclassification of acute lymphoblastic leukemia","volume":"6","author":"Chiaretti","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2021122309524252100_B7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/sj.leu.2401506","article-title":"Cytogenetic abnormalities associated with the t(12;21): A collaborative study of 169 children with t(12;21)-positive acute lymphoblastic leukemia","volume":"13","author":"Raynaud","year":"1999","journal-title":"Leukemia"},{"key":"2021122309524252100_B8","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret","year":"2002","journal-title":"Blood"},{"key":"2021122309524252100_B9","first-page":"1985","article-title":"TEL\/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis","volume":"9","author":"Shurtleff","year":"1995","journal-title":"Leukemia"},{"key":"2021122309524252100_B10","volume-title":"Cancer Facts & Figures 2015","author":"American Cancer Society","year":"2015"},{"key":"2021122309524252100_B11","doi-asserted-by":"crossref","first-page":"e85554","DOI":"10.1371\/journal.pone.0085554","article-title":"Survival of adults with acute lymphoblastic leukemia in Germany and the United States","volume":"9","author":"Pulte","year":"2014","journal-title":"PLoS One"},{"key":"2021122309524252100_B12","first-page":"131","article-title":"Acute lymphoblastic leukemia: Older patients and newer drugs","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Larson","year":"2005"},{"key":"2021122309524252100_B13","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"key":"2021122309524252100_B14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"2021122309524252100_B15","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"2021122309524252100_B16","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"2021122309524252100_B17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309524252100_B18","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309524252100_B19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.12225","article-title":"Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia","volume":"161","author":"Kako","year":"2013","journal-title":"Br J Haematol"},{"key":"2021122309524252100_B20","volume-title":"Spectrum Pharmaceuticals launches Marqibo (vinCRIStine sulfate LIPOSOME injection) and ships first commercial orders [press release]","year":"2013"},{"key":"2021122309524252100_B21","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/cncr.23919","article-title":"Outcome of adults with acute lymphocytic leukemia after second salvage therapy","volume":"113","author":"O\u2019Brien","year":"2008","journal-title":"Cancer"},{"key":"2021122309524252100_B22","first-page":"3479","article-title":"Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: Liposome-encapsulated vincristine","volume":"8","author":"Davis","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"2021122309524252100_B23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2592.2592","article-title":"Single-agent vincristine sulfate liposomes injection (Marqibo) compared to historical single-agent therapy for adults with advanced, relapsed and\/or refractory Philadelphia chromosome negative acute lymphoblastic leukemia","volume-title":"Poster presented at the 53rd ASH Annual Meeting and Exposition","author":"Deitcher","year":"2011"},{"key":"2021122309524252100_B24","volume-title":"FDA approves Marqibo to treat rare type of leukemia [press release]","year":"2012"},{"key":"2021122309524252100_B25","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"2021122309524252100_B26","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"2021122309524252100_B27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B Study 19802 [published correction appears in Cancer 2014;120:2222]","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer"},{"key":"2021122309524252100_B28","first-page":"802a","article-title":"Intensification of induction and consolidation improves only subgroups of adult ALL: Analysis of 1200 patients in GMALL study 05\/93","volume":"98","author":"G\u00f6kbuget","year":"2001","journal-title":"Blood"},{"key":"2021122309524252100_B29","first-page":"2741","article-title":"Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro","volume":"45","author":"Jordan","year":"1985","journal-title":"Cancer Res"},{"key":"2021122309524252100_B30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1008348010437","article-title":"Liposomal vincristine in relapsed non-Hodgkin\u2019s lymphomas: Early results of an ongoing phase II trial","volume":"11","author":"Sarris","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122309524252100_B31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/2040620713519016","article-title":"Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: A review of literature","volume":"5","author":"Pathak","year":"2014","journal-title":"Ther Adv Hematol"},{"key":"2021122309524252100_B32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1040-8428(98)00023-7","article-title":"Vincristine revisited","volume":"29","author":"Gidding","year":"1999","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122309524252100_B33","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1517\/17425255.2014.885016","article-title":"Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies","volume":"10","author":"Said","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2021122309524252100_B34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1124\/dmd.106.009902","article-title":"Selective metabolism of vincristine in vitro by CYP3A5","volume":"34","author":"Dennison","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"2021122309524252100_B35","first-page":"66","article-title":"Vincristine-induced cranial neuropathy","volume":"8","author":"Talebian","year":"2014","journal-title":"Iran J Child Neurol"},{"key":"2021122309524252100_B36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaapos.2003.07.010","article-title":"Acute sixth-nerve palsy after vincristine therapy","volume":"8","author":"Lash","year":"2004","journal-title":"J AAPOS"},{"key":"2021122309524252100_B37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF03259853","article-title":"Vincristine neurotoxicity. Pathophysiology and management","volume":"1","author":"Legha","year":"1986","journal-title":"Med Toxicol"},{"key":"2021122309524252100_B38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2012.46.8165","article-title":"It\u2019s ALL in the liposomes: Vincristine gets a new package","volume":"31","author":"Liesveld","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 20","key":"2021122309524252100_B39","first-page":"8","article-title":"Advances in the treatment of relapsed\/refractory ALL: Introduction to a case study compendium","volume":"12","author":"Douer","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"2021122309524252100_B40","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.1986.4.9.1295","article-title":"Twenty years of MOPP therapy for Hodgkin\u2019s disease","volume":"4","author":"Longo","year":"1986","journal-title":"J Clin Oncol"},{"key":"2021122309524252100_B41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJM199308193290817","article-title":"CHOP versus intensive regimens in non-Hodgkin\u2019s lymphoma","volume":"329","author":"Longo","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122309524252100_B42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/1097-0142(197307)32:1<52::AID-CNCR2820320107>3.0.CO;2-S","article-title":"MOPP chemotherapy for advanced Hodgkin\u2019s disease. Prognostic factors in 81 patients","volume":"32","author":"Moore","year":"1973","journal-title":"Cancer"},{"key":"2021122309524252100_B43","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1002\/1097-0142(19840615)53:12<2601::AID-CNCR2820531205>3.0.CO;2-D","article-title":"Treatment of advanced non-Hodgkin\u2019s lymphoma with vincristine infusion","volume":"53","author":"Jackson","year":"1984","journal-title":"Cancer"},{"key":"2021122309524252100_B44","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","article-title":"Nanomedicine therapeutic approaches to overcome cancer drug resistance","volume":"65","author":"Markman","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"2021122309524252100_B45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309524252100_B46","doi-asserted-by":"crossref","first-page":"939851","DOI":"10.1155\/2011\/939851","article-title":"A review on composite liposomal technologies for specialized drug delivery","volume":"2011","author":"Mufamadi","year":"2011","journal-title":"J Drug Deliv"},{"key":"2021122309524252100_B47","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/bjc.1995.98","article-title":"Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16\/BL6 solid tumours","volume":"71","author":"Mayer","year":"1995","journal-title":"Br J Cancer"},{"key":"2021122309524252100_B48","volume-title":"Marqibo [package insert]","year":"2013"},{"key":"2021122309524252100_B49","volume-title":"Psychiatric Times February 1, 2007","author":"Liposomal vincristine receives orphan drug designation for treatment of ALL"},{"key":"2021122309524252100_B50","first-page":"1206","article-title":"Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties","volume":"298","author":"Krishna","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122309524252100_B51","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00001813-199410000-00010","article-title":"Liposome encapsulated vincristine: Preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs","volume":"5","author":"Kanter","year":"1994","journal-title":"Anticancer Drugs"},{"key":"2021122309524252100_B52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s002800050846","article-title":"Preclinical pharmacology, toxicology and efficacy of sphingomyelin\/cholesterol liposomal vincristine for therapeutic treatment of cancer","volume":"42","author":"Webb","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309524252100_B53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/pharmaceutics6010137","article-title":"Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology","volume":"6","author":"Ait-Oudhia","year":"2014","journal-title":"Pharmaceutics"},{"key":"2021122309524252100_B54","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2012.46.2309","article-title":"High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"31","author":"O\u2019Brien","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 12","key":"2021122309524252100_B55","first-page":"18","article-title":"New developments in acute lymphoblastic leukemia","volume":"12","author":"Douer","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"2021122309524252100_B56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clml.2013.10.012","article-title":"High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity","volume":"14","author":"Deitcher","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122309524252100_B57","first-page":"575","article-title":"Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors","volume":"50","author":"Mayer","year":"1990","journal-title":"Cancer Res"},{"key":"2021122309524252100_B58","first-page":"2830","article-title":"Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors","volume":"54","author":"Boman","year":"1994","journal-title":"Cancer Res"},{"key":"2021122309524252100_B59","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1002\/cncr.24632","article-title":"Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia","volume":"115","author":"Thomas","year":"2009","journal-title":"Cancer"},{"key":"2021122309524252100_B60","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1177\/0091270010381499","article-title":"Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function","volume":"51","author":"Bedikian","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"2021122309524252100_B61","volume-title":"Hyper-CVAD with liposomal vincristine in acute lymphoblastic leukemia","author":"U.S. National Institutes of Health; MD Anderson Cancer Center"},{"key":"2021122309524252100_B62","volume-title":"Bortezomib and combination chemotherapy in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma","author":"U.S. National Institutes of Health; National Cancer Institute"},{"key":"2021122309524252100_B63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/asheducation.V2012.1.129.3800156","article-title":"Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?","volume":"2012","author":"Raetz","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122309524252100_B64","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"2021122309524252100_B65","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2141.2010.08236.x","article-title":"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma","volume":"150","author":"Commander","year":"2010","journal-title":"Br J Haematol"},{"key":"2021122309524252100_B66","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","article-title":"Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"118","author":"Hijiya","year":"2011","journal-title":"Blood"},{"key":"2021122309524252100_B67","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/pbc.24789","article-title":"Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia","volume":"61","author":"Shukla","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2021122309524252100_B68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"2021122309524252100_B69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122309524252100_B70","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2021122309524252100_B71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/14712598.2015.1024652","article-title":"Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin\u2019s lymphomas","volume":"15","author":"Ohanian","year":"2015","journal-title":"Expert Opin Biol Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0391","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/7\/840\/41874833\/oncolo_21_7_840.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/7\/840\/41874833\/oncolo_21_7_840.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:15:05Z","timestamp":1640319305000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/7\/840\/6401378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,21]]},"references-count":71,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,6,21]]},"published-print":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0391","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,7,1]]},"published":{"date-parts":[[2016,6,21]]}}}